Jeffrey H Lipton, PhD, MD, FRCPC

I am involved in clinical research at the phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted therapy with kinase inhibitors, drugs that may target the CML stem cell and cells that are resistant to other therapies. The interest in targeted therapy extends into the phase II study of signal transduction inhibitors in the therapy of other diseases such as systemic mastocytosis and mast cell leukemia.

The second aspect of my clinical research involves outcome analysis in allogeneic stem cell transplant and the prevention and therapy of side effects. I am particularly interested in donor selection, graft types and therapy of chronic side effects. I am also interested in long term effects on patients who are out beyond the initial post transplant period.
Leuk Lymphoma. 2019 Oct 24;:1-10
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH
Bone Marrow Transplant. 2019 Oct 14;:
Alblooshi RM, Deotare U, Michelis FV, Thyagu S, Kim DDH, Lipton JH, ElGohary GM, Viswabandya A
Eur J Haematol. 2019 Sep 23;:
Salas MQ, Atenafu EG, Bautista MR, Prem S, Lam W, Datt Law A, Shaibani ZA, Kim DDH, Michelis FV, Lipton JH, Viswabandya A, Mattsson J, Kumar R
Eur J Haematol. 2019 Sep 12;:
Salas MQ, Lam W, Law AD, Kim DDH, Michelis FV, Loach D, Al-Shaibani Z, Lipton JH, Kumar R, Mattsson J, Viswabandya A
Acta Haematol. 2019 Sep 12;:1-3
Bankar A, Lipton JH
Eur J Haematol. 2019 Aug 26;:
Salas MQ, Prem S, Atenafu EG, Law AD, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A
Eur J Haematol. 2019 Aug 16;:
Prem S, Atenafu EG, Avena J, Bautista R, Law A, Lam W, Michelis FV, Kim DDH, Viswabandya A, Lipton JH, Mattsson J, Kumar R
Eur J Haematol. 2019 Aug 07;:
Prem S, Al-Shaibani Z, Michelis FV, Kim D, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Law A, Lam W
Blood. 2019 Jul 04;134(1):6-7
Lipton JH
Biol Blood Marrow Transplant. 2019 Jun 04;:
Shapiro RM, Shin E, Law AD, Lam W, Michelis FV, Viswabandya A, Kumar R, Lipton JH, Messner H, Mattsson J, Kim DDH

Pages


 

Professor of Medicine, University of Toronto